You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameZolpidem
Accession NumberDB00425  (APRD00095)
TypeSmall Molecule
GroupsApproved
DescriptionZolpidem is a prescription short-acting nonbenzodiazepine hypnotic that potentiates gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, by binding to benzodiazepine receptors which are located on the gamma-aminobutyric acid receptors. Zolpidem is used for the short-term treatment of insomnia. It works quickly (usually within 15 minutes) and has a short half-life (2-3 hours). It is classified as an imidazopyridine. As an anticonvulsant and muscle relaxant, the beneficial effects start to emerge at 10 and 20 times the dose required for sedation, respectively. For that reason, it has never been approved for either muscle relaxation or seizure prevention. Recently, zolpidem has been cited in various medical reports mainly in the United Kingdom as waking persistent vegetative state (PVS) patients, and dramatically improving the conditions of people with brain injuries. [Wikipedia]
Structure
Thumb
Synonyms
N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide
Zolpidem
Zolpidemum
External Identifiers
  • HSDB 7045
  • SL 800750
  • SL 800750-23N
  • UNII-7K383OQI23
  • UNII-WY6W63843K
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmbienTablet, film coated5 mg/1OralA S Medication Solutions Llc1993-04-01Not applicableUs
AmbienTablet, film coated10 mg/1OralA S Medication Solutions Llc1993-04-01Not applicableUs
AmbienTablet, film coated5 mg/1OralRebel Distributors Corp.2009-06-30Not applicableUs
AmbienTablet, film coated5 mg/1OralSanofi Aventis U.S. Llc1993-04-01Not applicableUs
AmbienTablet, film coated5 mg/1OralA S Medication Solutions Llc1993-04-01Not applicableUs
AmbienTablet, film coated5 mg/1OralSTAT Rx USA LLC1993-04-01Not applicableUs
AmbienTablet, film coated10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2009-06-30Not applicableUs
AmbienTablet, film coated10 mg/1Oralbryant ranch prepack1993-04-01Not applicableUs
AmbienTablet, film coated10 mg/1OralRebel Distributors Corp.2009-06-30Not applicableUs
AmbienTablet, film coated10 mg/1OralSanofi Aventis U.S. Llc1993-04-01Not applicableUs
AmbienTablet, film coated10 mg/1OralA S Medication Solutions Llc1993-04-01Not applicableUs
AmbienTablet, film coated10 mg/1OralSTAT Rx USA LLC1993-04-01Not applicableUs
Ambien CRTablet, coated6.25 mg/1OralRebel Distributors Corp.2009-06-30Not applicableUs
Ambien CRTablet, coated6.25 mg/1OralSanofi Aventis U.S. Llc2005-09-19Not applicableUs
Ambien CRTablet, coated6.25 mg/1OralPhysicians Total Care, Inc.2005-10-07Not applicableUs
Ambien CRTablet, coated12.5 mg/1OralSTAT Rx USA LLC2009-06-30Not applicableUs
Ambien CRTablet6.25 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-10Not applicableUs
Ambien CRTablet, coated6.25 mg/1Oralbryant ranch prepack2009-06-30Not applicableUs
Ambien CRTablet, coated12.5 mg/1OralSanofi Aventis U.S. Llc2005-09-19Not applicableUs
Ambien CRTablet, coated12.5 mg/1OralSt Marys Medical Park Pharmacy2010-12-01Not applicableUs
Ambien CRTablet, coated12.5 mg/1OralA S Medication Solutions Llc2005-09-19Not applicableUs
Ambien CRTablet, coated12.5 mg/1OralPd Rx Pharmaceuticals, Inc.2009-06-30Not applicableUs
Ambien CRTablet, coated12.5 mg/1OralPhysicians Total Care, Inc.2009-11-24Not applicableUs
Ambien CRTablet, coated12.5 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-13Not applicableUs
Ambien CRTablet, coated12.5 mg/1Oralbryant ranch prepack2009-06-30Not applicableUs
Ambien CRTablet, coated12.5 mg/1OralRebel Distributors Corp.2009-06-30Not applicableUs
EdluarTablet10 mg/1OralMeda Pharmaceuticals Inc.2009-07-24Not applicableUs
EdluarTablet5 mg/1OralMeda Pharmaceuticals Inc.2009-07-24Not applicableUs
IntermezzoTablet1.75 mg/1SublingualPurdue Pharma LP2012-04-05Not applicableUs
IntermezzoTablet3.5 mg/1SublingualPurdue Pharma LP2012-04-05Not applicableUs
IvadalTablet5 mgOralSanofi Aventis Canada IncNot applicableNot applicableCanada
IvadalTablet10 mgOralSanofi Aventis Canada IncNot applicableNot applicableCanada
SublinoxTablet, orally disintegrating10 mgSublingualValeant Canada Lp/valeant Canada s.e.c.2011-11-29Not applicableCanada
SublinoxTablet, orally disintegrating5 mgSublingualValeant Canada Lp Valeant Canada S.E.C.2013-01-28Not applicableCanada
Zolpidem TartrateTablet, film coated, extended release6.25 mg/1OralWinthrop U.S, A Business Of Sanofi Aventis U.S. Llc2010-10-14Not applicableUs
Zolpidem TartrateTablet, film coated, extended release12.5 mg/1OralWinthrop U.S, A Business Of Sanofi Aventis U.S. Llc2010-12-06Not applicableUs
Zolpidem TartrateTablet, film coated, extended release12.5 mg/1OralAphena Pharma Solutions Tennessee, Llc2010-12-06Not applicableUs
Zolpidem TartrateTablet, film coated, extended release12.5 mg/1OralPhysicians Total Care, Inc.2010-12-16Not applicableUs
Zolpidem TartrateTablet, coated5 mg/1OralKAISER FOUNDATION HOSPITALS2008-10-01Not applicableUs
Zolpidem TartrateTablet, coated10 mg/1OralKAISER FOUNDATION HOSPITALS2008-10-01Not applicableUs
Zolpidem TartrateTablet, film coated, extended release12.5 mg/1OralA S Medication Solutions2010-12-06Not applicableUs
Zolpidem Tartrate ODTTablet, orally disintegrating5 mgSublingualValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
Zolpidem Tartrate ODTTablet, orally disintegrating10 mgSublingualValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
ZolpimistSpray, metered5 mg/1OralECR Pharmaceuticals2010-12-01Not applicableUs
ZolpimistSpray, metered5 mg/1OralMagna Pharmaceuticals, Inc.2016-03-21Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmbienTablet10 mg/1OralDIRECT RX2016-01-28Not applicableUs
AmbienTablet5 mg/1OralDIRECT RX2016-02-10Not applicableUs
Apo-zolpidem ODTTablet, orally disintegrating10 mgSublingualApotex Inc2015-02-13Not applicableCanada
Apo-zolpidem ODTTablet, orally disintegrating5 mgSublingualApotex Inc2015-02-13Not applicableCanada
ZolpidemTablet5 mg/1OralWest ward Pharmaceutical Corp2008-04-30Not applicableUs
ZolpidemTablet10 mg/1OralWest ward Pharmaceutical Corp2008-04-30Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralProficient Rx LP2007-04-23Not applicableUs
Zolpidem TartrateTablet10 mg/1OralPreferred Pharmaceuticals, Inc.2007-09-05Not applicableUs
Zolpidem TartrateTablet10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-09-05Not applicableUs
Zolpidem TartrateTablet5 mg/1OralSTAT Rx USA LLC2007-09-05Not applicableUs
Zolpidem TartrateTablet, film coated, extended release6.25 mg/1OralWatson Laboratories, Inc.2013-03-25Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralAphena Pharma Solutions Tennessee, Llc2008-11-21Not applicableUs
Zolpidem TartrateTablet10 mg/1OralH.J. Harkins Company, Inc.2007-09-05Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralCardinal Health2007-04-23Not applicableUs
Zolpidem TartrateTablet5 mg/1OralCarlsbad Technology, Inc.2007-04-23Not applicableUs
Zolpidem TartrateTablet5 mg/1Oralbryant ranch prepack2007-09-05Not applicableUs
Zolpidem TartrateTablet, coated10 mg/1OralAmerican Health Packaging2014-01-07Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralDispensing Solutions, Inc.2008-11-21Not applicableUs
Zolpidem TartrateTablet, extended release12.5 mg/1OralSandoz Inc2011-10-31Not applicableUs
Zolpidem TartrateTablet1.75 mg/1SublingualNovel Laboratories, Inc.2016-03-22Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralBlenheim Pharmacal, Inc.2013-10-03Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralRoxane Laboratories, Inc2007-04-27Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-04-27Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralUnit Dose Services2008-11-21Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralDr. Reddy's Laboratories Limited2007-04-23Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2010-12-10Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralProficient Rx LP2008-11-21Not applicableUs
Zolpidem TartrateTablet5 mg/1OralMajor Pharmaceuticals2007-09-05Not applicableUs
Zolpidem TartrateTablet10 mg/1OralAidarex Pharmaceuticals LLC2007-09-05Not applicableUs
Zolpidem TartrateTablet5 mg/1OralA S Medication Solutions Llc2007-09-05Not applicableUs
Zolpidem TartrateTablet, film coated, extended release6.25 mg/1OralA S Medication Solutions Llc2010-10-13Not applicableUs
Zolpidem TartrateTablet10 mg/1OralCardinal Health2011-01-28Not applicableUs
Zolpidem TartrateTablet10 mg/1OralDIRECT RX2015-12-02Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2011-06-01Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralMc Kesson Contract Packaging2011-10-20Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralMylan Pharmaceuticals Inc.2007-04-23Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-30Not applicableUs
Zolpidem TartrateTablet, coated5 mg/1OralProficient Rx LP2007-04-23Not applicableUs
Zolpidem TartrateTablet5 mg/1OralTorrent Pharmaceuticals Limited2007-09-05Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralKAISER FOUNDATION HOSPITALS2015-09-15Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2008-11-21Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralMylan Institutional Inc.2007-05-01Not applicableUs
Zolpidem TartrateTablet5 mg/1OralCardinal Health2009-10-14Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralApotex Corp.2007-04-23Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralRanbaxy Pharmaceuticals Inc.2007-04-23Not applicableUs
Zolpidem TartrateTablet10 mg/1OralRed Pharm Drug Inc.2008-11-21Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralAurobindo Pharma Limited2007-05-04Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-04-23Not applicableUs
Zolpidem TartrateTablet, extended release12.5 mg/1Oralbryant ranch prepack2011-10-31Not applicableUs
Zolpidem TartrateTablet, film coated, extended release12.5 mg/1OralAmerican Health Packaging2011-12-01Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralTeva Pharmaceuticals USA Inc2007-04-23Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralPreferred Pharmaceuticals, Inc.2015-02-23Not applicableUs
Zolpidem TartrateTablet5 mg/1OralRebel Distributors Corp.2007-09-05Not applicableUs
Zolpidem TartrateTablet, film coated, extended release12.5 mg/1OralWatson Laboratories, Inc.2013-03-25Not applicableUs
Zolpidem TartrateTablet10 mg/1OralMedsource Pharmaceuticals2007-09-05Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralA S Medication Solutions Llc2008-11-21Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralCardinal Health2007-04-232016-03-11Us
Zolpidem TartrateTablet10 mg/1OralCarlsbad Technology, Inc.2007-04-23Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralWockhardt Limited2007-05-15Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralProficient Rx LP2008-11-21Not applicableUs
Zolpidem TartrateTablet10 mg/1OralMajor Pharmaceuticals2007-09-05Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralDispensing Solutions, Inc.2008-11-21Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralNorth Star Rx Llc2007-05-04Not applicableUs
Zolpidem TartrateTablet3.5 mg/1SublingualLupin Pharmaceuticals,inc.2016-03-22Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralBlenheim Pharmacal, Inc.2011-01-07Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralRoxane Laboratories, Inc2007-04-27Not applicableUs
Zolpidem TartrateTablet, film coated, extended release6.25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-10-13Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralUnit Dose Services2008-11-21Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralDr. Reddy's Laboratories Limited2007-04-23Not applicableUs
Zolpidem TartrateTablet10 mg/1OralRx Change Co.2014-11-20Not applicableUs
Zolpidem TartrateTablet10 mg/1OralA S Medication Solutions Llc2007-09-05Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralPhysicians Total Care, Inc.2007-10-09Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralCardinal Health2007-04-23Not applicableUs
Zolpidem TartrateTablet5 mg/1OralDIRECT RX2015-01-01Not applicableUs
Zolpidem TartrateTablet5 mg/1OralWockhardt USA LLC.2007-05-15Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralMc Kesson Contract Packaging2011-10-21Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralQualitest Pharmaceuticals2008-11-212016-12-31Us
Zolpidem TartrateTablet5 mg/1OralPd Rx Pharmaceuticals, Inc.2007-09-05Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralProficient Rx LP2007-04-23Not applicableUs
Zolpidem TartrateTablet10 mg/1OralTorrent Pharmaceuticals Limited2007-09-05Not applicableUs
Zolpidem TartrateTablet, film coated, extended release6.25 mg/1OralActavis Pharma, Inc.2010-10-13Not applicableUs
Zolpidem TartrateTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.2007-09-05Not applicableUs
Zolpidem TartrateTablet10 mg/1OralREMEDYREPACK INC.2013-05-22Not applicableUs
Zolpidem TartrateTablet10 mg/1OralCardinal Health2009-10-14Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralRanbaxy Pharmaceuticals Inc.2007-04-23Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralRed Pharm Drug Inc.2008-11-21Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralAurobindo Pharma Limited2007-05-04Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-04-23Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralCardinal Health2007-04-232016-03-11Us
Zolpidem TartrateTablet, film coated10 mg/1OralDIRECT RX2014-01-01Not applicableUs
Zolpidem TartrateTablet, extended release6.25 mg/1Oralbryant ranch prepack2011-10-31Not applicableUs
Zolpidem TartrateTablet, film coated, extended release6.25 mg/1OralAmerican Health Packaging2014-12-15Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralTeva Pharmaceuticals USA Inc2007-04-23Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralPreferred Pharmaceuticals, Inc.2015-02-23Not applicableUs
Zolpidem TartrateTablet10 mg/1OralRebel Distributors Corp.2007-09-05Not applicableUs
Zolpidem TartrateTablet, coated5 mg/1OralSandoz Inc2007-04-23Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-04-15Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralA S Medication Solutions Llc2008-11-21Not applicableUs
Zolpidem TartrateTablet, extended release12.5 mg/1OralUnit Dose Services2011-10-31Not applicableUs
Zolpidem TartrateTablet5 mg/1OralCardinal Health2009-11-02Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralWockhardt Limited2007-05-15Not applicableUs
Zolpidem TartrateTablet5 mg/1OralProficient Rx LP2007-09-05Not applicableUs
Zolpidem TartrateTablet5 mg/1SublingualPar Pharmaceutical, Inc.2015-03-12Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralRed Pharm Drug, Inc.2007-05-04Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralPreferred Pharmaceuticals Inc.2016-01-20Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralNorth Star Rx Llc2007-05-04Not applicableUs
Zolpidem TartrateTablet1.75 mg/1SublingualLupin Pharmaceuticals,inc.2016-03-22Not applicableUs
Zolpidem TartrateTablet5 mg/1OralApotheca, Inc2007-07-25Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralSTAT Rx USA LLC2008-11-21Not applicableUs
Zolpidem TartrateTablet5 mg/1OralRx Change Co.2014-11-27Not applicableUs
Zolpidem TartrateTablet10 mg/1OralBlenheim Pharmacal, Inc.2011-03-11Not applicableUs
Zolpidem TartrateTablet, film coated, extended release12.5 mg/1OralA S Medication Solutions Llc2011-06-07Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralPhysicians Total Care, Inc.2009-07-01Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralCardinal Health2007-04-23Not applicableUs
Zolpidem TartrateTablet, extended release12.5 mg/1OralDIRECT RX2014-01-01Not applicableUs
Zolpidem TartrateTablet10 mg/1OralWockhardt USA LLC.2007-05-15Not applicableUs
Zolpidem TartrateTablet5 mg/1OralAmerican Health Packaging2009-10-142015-12-29Us
Zolpidem TartrateTablet, film coated10 mg/1OralQualitest Pharmaceuticals2008-11-212016-12-31Us
Zolpidem TartrateTablet, film coated10 mg/1OralREMEDYREPACK INC.2016-02-12Not applicableUs
Zolpidem TartrateTablet, extended release6.25 mg/1OralLupin Pharmaceuticals, Inc.2014-04-07Not applicableUs
Zolpidem TartrateTablet10 mg/1OralSTAT Rx USA LLC2007-09-05Not applicableUs
Zolpidem TartrateTablet, film coated, extended release12.5 mg/1OralActavis Pharma, Inc.2011-06-07Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralAphena Pharma Solutions Tennessee, Llc2008-11-21Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralREMEDYREPACK INC.2013-06-102016-10-13Us
Zolpidem TartrateTablet, film coated5 mg/1OralCardinal Health2007-04-23Not applicableUs
Zolpidem TartrateTablet5 mg/1OralSt Marys Medical Park Pharmacy2007-09-05Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1Oralbryant ranch prepack2008-11-21Not applicableUs
Zolpidem TartrateTablet, coated5 mg/1OralAmerican Health Packaging2014-01-07Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralPreferred Pharmaceuticals Inc.2016-01-11Not applicableUs
Zolpidem TartrateTablet5 mg/1OralPreferred Pharmaceuticals, Inc.2007-09-05Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-04-23Not applicableUs
Zolpidem TartrateTablet, coated10 mg/1OralSandoz Inc2007-04-23Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-11-07Not applicableUs
Zolpidem TartrateTablet, film coated, extended release12.5 mg/1OralA S Medication Solutions Llc2011-06-07Not applicableUs
Zolpidem TartrateTablet5 mg/1OralCardinal Health2011-01-28Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralDIRECT RX2014-01-01Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1Oralbryant ranch prepack2008-11-21Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralLife Line Home Care Services, Inc.2008-11-21Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralMylan Pharmaceuticals Inc.2007-04-23Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-30Not applicableUs
Zolpidem TartrateTablet, coated10 mg/1OralProficient Rx LP2007-04-23Not applicableUs
Zolpidem TartrateTablet5 mg/1OralAidarex Pharmaceuticals LLC2007-09-05Not applicableUs
Zolpidem TartrateTablet10 mg/1OralApotheca, Inc2007-09-25Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2010-12-10Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralMylan Institutional Inc.2007-05-01Not applicableUs
Zolpidem TartrateTablet10 mg/1OralCardinal Health2009-11-02Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralApotex Corp.2007-04-23Not applicableUs
Zolpidem TartrateTablet10 mg/1OralProficient Rx LP2007-09-05Not applicableUs
Zolpidem TartrateTablet10 mg/1SublingualPar Pharmaceutical, Inc.2015-03-12Not applicableUs
Zolpidem TartrateTablet5 mg/1OralRed Pharm Drug Inc.2007-09-05Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralREMEDYREPACK INC.2014-12-15Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-04-23Not applicableUs
Zolpidem TartrateTablet, extended release12.5 mg/1OralLupin Pharmaceuticals, Inc.2014-04-07Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-04-27Not applicableUs
Zolpidem TartrateTablet, film coated10 mg/1OralBlenheim Pharmacal, Inc.2013-10-03Not applicableUs
Zolpidem TartrateTablet, film coated, extended release6.25 mg/1OralA S Medication Solutions Llc2010-10-13Not applicableUs
Zolpidem TartrateTablet, film coated, extended release6.25 mg/1OralPhysicians Total Care, Inc.2010-11-02Not applicableUs
Zolpidem TartrateTablet, film coated5 mg/1OralPd Rx Pharmaceuticals, Inc.2008-11-21Not applicableUs
Zolpidem TartrateTablet, extended release12.5 mg/1OralProficient Rx LP2011-10-31Not applicableUs
Zolpidem TartrateTablet10 mg/1OralTYA Pharmaceuticals2007-09-05Not applicableUs
Zolpidem TartrateTablet10 mg/1OralAmerican Health Packaging2009-10-142015-12-29Us
Zolpidem TartrateTablet, extended release6.25 mg/1OralSandoz Inc2011-10-31Not applicableUs
Zolpidem TartrateTablet3.5 mg/1SublingualNovel Laboratories, Inc.2016-03-22Not applicableUs
Zolpidem Tartrate Extended ReleaseTablet, film coated, extended release12.5 mg/1OralSt Marys Medical Park Pharmacy2013-01-10Not applicableUs
Zolpidem Tartrate Extended-releaseTablet, film coated, extended release12.5 mg/1OralPar Pharmaceutical, Inc.2011-12-06Not applicableUs
Zolpidem Tartrate Extended-releaseTablet, film coated, extended release12.5 mg/1OralGolden State Medical Supply, Inc.2015-09-15Not applicableUs
Zolpidem Tartrate Extended-releaseTablet, film coated, extended release6.25 mg/1OralPar Pharmaceutical, Inc.2011-04-14Not applicableUs
Zolpidem Tartrate Extended-releaseTablet, film coated, extended release12.5 mg/1OralAvera Mc Kennan Hospital2015-06-29Not applicableUs
Zolpidem Tartrate Extended-releaseTablet, film coated, extended release6.25 mg/1OralGolden State Medical Supply, Inc.2015-09-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdormixSanofi Pasteur
Bikalmsanofi-aventis
Dormizolsanofi-aventis
HypnogenZentiva
IvedalWinthrop
NasenPolfarmex
NimadormSandoz
Nottemsanofi-aventis
Stilnoctsanofi-aventis
Stilnoxsanofi-aventis
Stilnox CRsanofi-aventis
ZolsanaKrka
ZoltisBiofarm
Brand mixtures
NameLabellerIngredients
Gabazolpidem-5Physician Therapeutics Llc
Sentrazolpidem PM-5Physician Therapeutics Llc
Salts
Name/CASStructureProperties
Zolpidem tartrate
ThumbNot applicableDBSALT001047
Categories
UNII7K383OQI23
CAS number82626-48-0
WeightAverage: 307.3895
Monoisotopic: 307.168462309
Chemical FormulaC19H21N3O
InChI KeyZAFYATHCZYHLPB-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3
IUPAC Name
N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide
SMILES
CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
Pharmacology
IndicationFor the short-term treatment of insomnia.
Structured Indications
PharmacodynamicsZolpidem is a sedative or hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties. It interacts with a GABA-BZ receptor complex and shares some of the pharmacological properties of the benzodiazepines. In contrast to the benzodiazepines, which non-selectively bind to and activate all three alpha receptor subtypes, zolpidem in vitro binds the (alpha1) receptor preferentially. The (alpha1) receptor is found primarily on the Lamina IV of the sensorimotor cortical regions, substantia nigra (pars reticulata), cerebellum molecular layer, olfactory bulb, ventral thalamic complex, pons, inferior colliculus, and globus pallidus.
Mechanism of actionZolpidem modulates the alpha-subunit, known as the benzodiazepine receptor, within the GABAA receptor chloride channel macromolecular complex. Unlike the benzodiazepines, which non-selectively interact with all three alpha-receptor subtypes, Zolpidem preferentially binds to the alpha-1 receptor.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
potentiator
HumanP14867 details
Gamma-aminobutyric acid receptor subunit alpha-2Proteinunknown
agonist
HumanP47869 details
Gamma-aminobutyric acid receptor subunit alpha-3Proteinunknown
agonist
HumanP34903 details
Related Articles
AbsorptionZolpidem is rapidly absorbed from the GI tract.
Volume of distributionNot Available
Protein binding92.5 ± 0.1% (independent of concentration between 40 and 790 ng/mL)
Metabolism

Zolpidem is converted to inactive metabolites in the liver.

SubstrateEnzymesProduct
Zolpidem
Methoxyzolpidem derivative (M3)Details
Zolpidem
Methoxyzolpidem derivative (M4)Details
Zolpidem
Not Available
Methoxyzolpidem derivative (M11)Details
Methoxyzolpidem derivative (M4)
Not Available
Zolpidem carboxylic acid derivative (M2)Details
Methoxyzolpidem derivative (M3)
Not Available
Zolpidem carboxylic acid derivative (M1)Details
Route of eliminationZolpidem tartrate tablets are converted to inactive metabolites that are eliminated primarily by renal excretion.
Half life2.6 hours
ClearanceNot Available
ToxicityOral (male rat) LD50 = 695 mg/kg. Symptoms of overdose include impairment of consciousness ranging from somnolence to light coma.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 Tetrafluoroethane1,1,1,2 Tetrafluoroethane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
2-HYDROXY-1,4-NAPHTHOQUINONEThe serum concentration of Zolpidem can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe serum concentration of Zolpidem can be increased when it is combined with 2-mercaptobenzothiazole.Vet Approved
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Experimental
AbirateroneThe serum concentration of Zolpidem can be increased when it is combined with Abiraterone.Approved
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
adipiplonadipiplon may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Vet Approved
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Experimental, Illicit
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Zolpidem can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
AmorolfineThe serum concentration of Zolpidem can be increased when it is combined with Amorolfine.Approved
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Experimental
Amphotericin BThe serum concentration of Zolpidem can be increased when it is combined with Amphotericin B.Approved, Investigational
AN2690The serum concentration of Zolpidem can be increased when it is combined with AN2690.Investigational
AnidulafunginThe serum concentration of Zolpidem can be increased when it is combined with Anidulafungin.Approved, Investigational
AprepitantThe serum concentration of Zolpidem can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
ArmodafinilThe metabolism of Zolpidem can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe serum concentration of Zolpidem can be increased when it is combined with Artemether.Approved
ArticaineArticaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
AtazanavirThe metabolism of Zolpidem can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Zolpidem can be decreased when combined with Atomoxetine.Approved
AzaperoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Vet Approved
AzelastineZolpidem may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe metabolism of Zolpidem can be decreased when combined with Azithromycin.Approved
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
Bafilomycin A1The serum concentration of Zolpidem can be increased when it is combined with Bafilomycin A1.Experimental
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Illicit
BenperidolBenperidol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
BenzocaineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
Benzoic AcidThe serum concentration of Zolpidem can be increased when it is combined with Benzoic Acid.Approved
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
BetaxololThe metabolism of Zolpidem can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Zolpidem can be decreased when it is combined with Bexarotene.Approved, Investigational
BifonazoleThe serum concentration of Zolpidem can be increased when it is combined with Bifonazole.Approved
BoceprevirThe metabolism of Zolpidem can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Zolpidem can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Zolpidem can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Withdrawn
BupivacaineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
BuprenorphineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Zolpidem can be decreased when combined with Bupropion.Approved
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
ButacaineButacaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Vet Approved
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
ButambenButamben may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ButenafineThe serum concentration of Zolpidem can be increased when it is combined with Butenafine.Approved
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
ButoconazoleThe serum concentration of Zolpidem can be increased when it is combined with Butoconazole.Approved
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit, Vet Approved
CaffeineThe metabolism of Zolpidem can be decreased when combined with Caffeine.Approved
CandicidinThe serum concentration of Zolpidem can be increased when it is combined with Candicidin.Withdrawn
CapecitabineThe metabolism of Zolpidem can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineZolpidem may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Illicit, Vet Approved
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
CaspofunginThe serum concentration of Zolpidem can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Zolpidem can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Zolpidem can be increased when it is combined with Ceritinib.Approved
CeruleninThe serum concentration of Zolpidem can be increased when it is combined with Cerulenin.Approved
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Zolpidem can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Withdrawn
ChloroprocaineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ChloroquineThe metabolism of Zolpidem can be decreased when combined with Chloroquine.Approved, Vet Approved
ChloroxineThe serum concentration of Zolpidem can be increased when it is combined with Chloroxine.Approved
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Withdrawn
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
CholecalciferolThe metabolism of Zolpidem can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclopiroxThe serum concentration of Zolpidem can be increased when it is combined with Ciclopirox.Approved, Investigational
CimetidineThe metabolism of Zolpidem can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Zolpidem can be decreased when combined with Cinacalcet.Approved
CinchocaineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
CitalopramThe metabolism of Zolpidem can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Zolpidem can be decreased when combined with Clarithromycin.Approved
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
clomethiazoleclomethiazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
ClotrimazoleThe serum concentration of Zolpidem can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
CobicistatThe serum concentration of Zolpidem can be increased when it is combined with Cobicistat.Approved
CocaineCocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
ConivaptanThe serum concentration of Zolpidem can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinThe serum concentration of Zolpidem can be increased when it is combined with Cordycepin.Investigational
CrizotinibThe metabolism of Zolpidem can be decreased when combined with Crizotinib.Approved
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
CyclosporineThe serum concentration of Zolpidem can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
Cyproterone acetateThe serum concentration of Zolpidem can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Zolpidem can be decreased when it is combined with Dabrafenib.Approved
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Zolpidem can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Zolpidem can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Zolpidem can be increased when it is combined with Dasatinib.Approved, Investigational
Decanoic AcidThe serum concentration of Zolpidem can be increased when it is combined with Decanoic Acid.Experimental
DeferasiroxThe serum concentration of Zolpidem can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Zolpidem can be decreased when combined with Delavirdine.Approved
deramciclanederamciclane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Desvenlafaxine.Approved
DetomidineDetomidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Vet Approved
DexamethasoneThe serum concentration of Zolpidem can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
DexmedetomidineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit, Withdrawn
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit, Vet Approved
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
DihydroergotamineThe metabolism of Zolpidem can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Experimental, Illicit
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Experimental, Illicit
DiltiazemThe metabolism of Zolpidem can be decreased when combined with Diltiazem.Approved
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
DoramectinDoramectin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Vet Approved
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
DoxycyclineThe metabolism of Zolpidem can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
DPDPEDPDPE may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
DronedaroneThe metabolism of Zolpidem can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Experimental, Illicit
DuloxetineThe metabolism of Zolpidem can be decreased when combined with Duloxetine.Approved
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
EcgonineEcgonine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Experimental, Illicit
ECGONINE METHYL ESTERECGONINE METHYL ESTER may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Experimental
EconazoleThe serum concentration of Zolpidem can be increased when it is combined with Econazole.Approved
EcopipamEcopipam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
EfinaconazoleThe serum concentration of Zolpidem can be increased when it is combined with Efinaconazole.Approved
EliglustatThe metabolism of Zolpidem can be decreased when combined with Eliglustat.Approved
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
EnzalutamideThe serum concentration of Zolpidem can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Zolpidem can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Zolpidem is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Zolpidem can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Zolpidem can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit, Withdrawn
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Withdrawn
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
EtidocaineEtidocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Withdrawn
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
EtomidateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Etoperidone.Approved
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Illicit, Vet Approved
EtravirineThe serum concentration of Zolpidem can be decreased when it is combined with Etravirine.Approved
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit, Withdrawn
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit, Investigational, Vet Approved
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
FloxuridineThe metabolism of Zolpidem can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Zolpidem can be increased when it is combined with Fluconazole.Approved
FlucytosineThe serum concentration of Zolpidem can be increased when it is combined with Flucytosine.Approved
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
FlumazenilFlumazenil may decrease the sedative activities of Zolpidem.Approved
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
FluorouracilThe metabolism of Zolpidem can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Zolpidem can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Withdrawn
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
Fluticasone PropionateFluticasone Propionate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
FluvastatinThe metabolism of Zolpidem can be decreased when combined with Fluvastatin.Approved
FluvoxamineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
FosamprenavirThe metabolism of Zolpidem can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Zolpidem can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
Fusidic AcidThe serum concentration of Zolpidem can be increased when it is combined with Fusidic Acid.Approved
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
gabapentin enacarbilgabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
GemfibrozilThe metabolism of Zolpidem can be decreased when combined with Gemfibrozil.Approved
GepironeGepirone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
GlyphosateThe serum concentration of Zolpidem can be increased when it is combined with Glyphosate.Experimental
GriseofulvinThe serum concentration of Zolpidem can be increased when it is combined with Griseofulvin.Approved, Vet Approved
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
HaloproginThe serum concentration of Zolpidem can be increased when it is combined with Haloprogin.Approved, Withdrawn
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
HexetidineThe serum concentration of Zolpidem can be increased when it is combined with Hexetidine.Approved
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
HydrocodoneZolpidem may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
IdelalisibThe serum concentration of Zolpidem can be increased when it is combined with Idelalisib.Approved
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ImatinibThe metabolism of Zolpidem can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
IndalpineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Zolpidem can be decreased when combined with Indinavir.Approved
IrbesartanThe metabolism of Zolpidem can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Zolpidem can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe serum concentration of Zolpidem can be increased when it is combined with Isoconazole.Approved
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
IsoniazidThe metabolism of Zolpidem can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Zolpidem can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Zolpidem can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Zolpidem can be increased when it is combined with Ivacaftor.Approved
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
KetoconazoleThe serum concentration of Zolpidem can be increased when it is combined with Ketoconazole.Approved, Investigational
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
LeflunomideThe metabolism of Zolpidem can be decreased when combined with Leflunomide.Approved, Investigational
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
LevobupivacaineLevobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Zolpidem is combined with Levomilnacipran.Approved
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
LidocaineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
LithiumLithium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Illicit
LopinavirThe metabolism of Zolpidem can be decreased when combined with Lopinavir.Approved
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
LorcaserinThe metabolism of Zolpidem can be decreased when combined with Lorcaserin.Approved
LosartanThe metabolism of Zolpidem can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Zolpidem can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
Lu AA21004Lu AA21004 may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
LuliconazoleThe serum concentration of Zolpidem can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Zolpidem can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Zolpidem can be decreased when combined with Lumefantrine.Approved
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
MedetomidineMedetomidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Vet Approved
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
MepivacaineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Withdrawn
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Illicit, Withdrawn
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
MethotrimeprazineZolpidem may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
MetoprololThe metabolism of Zolpidem can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineZolpidem may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Zolpidem can be increased when it is combined with Mevastatin.Experimental
MexiletineThe metabolism of Zolpidem can be decreased when combined with Mexiletine.Approved
MicafunginThe serum concentration of Zolpidem can be increased when it is combined with Micafungin.Approved, Investigational
MiconazoleThe serum concentration of Zolpidem can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
MifepristoneThe serum concentration of Zolpidem can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Zolpidem is combined with Milnacipran.Approved
MiltefosineThe serum concentration of Zolpidem can be increased when it is combined with Miltefosine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
MirabegronThe metabolism of Zolpidem can be decreased when combined with Mirabegron.Approved
MirtazapineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
MitotaneThe serum concentration of Zolpidem can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Zolpidem can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Zolpidem can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
MonensinThe serum concentration of Zolpidem can be increased when it is combined with Monensin.Vet Approved
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
MyxothiazolThe serum concentration of Zolpidem can be increased when it is combined with Myxothiazol.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
NafcillinThe serum concentration of Zolpidem can be decreased when it is combined with Nafcillin.Approved
NaftifineThe serum concentration of Zolpidem can be increased when it is combined with Naftifine.Approved
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
NatamycinThe serum concentration of Zolpidem can be increased when it is combined with Natamycin.Approved
NefazodoneThe metabolism of Zolpidem can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Zolpidem can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Zolpidem can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Zolpidem can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Zolpidem can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Zolpidem can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
NitroxolineThe serum concentration of Zolpidem can be increased when it is combined with Nitroxoline.Approved
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
NystatinThe serum concentration of Zolpidem can be increased when it is combined with Nystatin.Approved, Vet Approved
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
OlaparibThe metabolism of Zolpidem can be decreased when combined with Olaparib.Approved
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
OmeprazoleThe metabolism of Zolpidem can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
OrphenadrineZolpidem may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
OsimertinibThe serum concentration of Zolpidem can be increased when it is combined with Osimertinib.Approved
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
OxetacaineOxetacaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
OxiconazoleThe serum concentration of Zolpidem can be increased when it is combined with Oxiconazole.Approved
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
OxybuprocaineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational, Vet Approved
pafuramidineThe serum concentration of Zolpidem can be increased when it is combined with pafuramidine.Investigational
PalbociclibThe serum concentration of Zolpidem can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
PanobinostatThe serum concentration of Zolpidem can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Zolpidem can be decreased when combined with Pantoprazole.Approved
ParaldehydeZolpidem may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Zolpidem can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Zolpidem can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe serum concentration of Zolpidem can be increased when it is combined with Pentamidine.Approved
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
PerazinePerazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
PhenoxyethanolPhenoxyethanol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
PiritramidePiritramide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
PosaconazoleThe serum concentration of Zolpidem can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleZolpidem may increase the sedative activities of Pramipexole.Approved, Investigational
PramocainePramocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit, Investigational
PregnanolonePregnanolone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
PrilocainePrilocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational, Vet Approved
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ProparacaineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
PSD502PSD502 may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
PyrimethamineThe metabolism of Zolpidem can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
QuinidineThe metabolism of Zolpidem can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Zolpidem can be decreased when combined with Quinine.Approved
RacloprideRaclopride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
RadicicolThe serum concentration of Zolpidem can be increased when it is combined with Radicicol.Experimental
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
RanolazineThe metabolism of Zolpidem can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Withdrawn
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
RifabutinThe serum concentration of Zolpidem can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Zolpidem can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Zolpidem can be decreased when it is combined with Rifapentine.Approved
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
RitanserinRitanserin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
RitonavirThe metabolism of Zolpidem can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Zolpidem can be decreased when combined with Rolapitant.Approved
RomifidineRomifidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Vet Approved
RopiniroleZolpidem may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
RotigotineZolpidem may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Zolpidem.Approved
S-EthylisothioureaS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Experimental
Sage 547Sage 547 may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
Salicylhydroxamic AcidThe serum concentration of Zolpidem can be increased when it is combined with Salicylhydroxamic Acid.Experimental
Salicylic acidThe serum concentration of Zolpidem can be increased when it is combined with Salicylic acid.Approved, Vet Approved
SaquinavirThe metabolism of Zolpidem can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
SertaconazoleThe serum concentration of Zolpidem can be increased when it is combined with Sertaconazole.Approved
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Withdrawn
SertralineThe metabolism of Zolpidem can be decreased when combined with Sertraline.Approved
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
SildenafilThe metabolism of Zolpidem can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Zolpidem can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Zolpidem can be increased when it is combined with Simeprevir.Approved
SinefunginThe serum concentration of Zolpidem can be increased when it is combined with Sinefungin.Experimental
SirolimusThe serum concentration of Zolpidem can be increased when it is combined with Sirolimus.Approved, Investigational
Sodium oxybateZolpidem may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
SorafenibThe metabolism of Zolpidem can be decreased when combined with Sorafenib.Approved, Investigational
St. John's WortThe serum concentration of Zolpidem can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolStiripentol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
SulconazoleThe serum concentration of Zolpidem can be increased when it is combined with Sulconazole.Approved
SulfadiazineThe metabolism of Zolpidem can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Zolpidem can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Zolpidem can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
SuvorexantZolpidem may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeTandospirone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
TavaboroleThe serum concentration of Zolpidem can be increased when it is combined with Tavaborole.Approved
TelaprevirThe serum concentration of Zolpidem can be decreased when it is combined with Telaprevir.Approved
TelithromycinThe metabolism of Zolpidem can be decreased when combined with Telithromycin.Approved
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
TenofovirThe metabolism of Zolpidem can be decreased when combined with Tenofovir.Approved, Investigational
TerbinafineThe serum concentration of Zolpidem can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe serum concentration of Zolpidem can be increased when it is combined with Terconazole.Approved
TeriflunomideThe serum concentration of Zolpidem can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
TetracaineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
ThalidomideZolpidem may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Zolpidem can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
ThioridazineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ThymolThe serum concentration of Zolpidem can be increased when it is combined with Thymol.Approved
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
TiaprideTiapride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
TicagrelorThe metabolism of Zolpidem can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Zolpidem can be decreased when combined with Ticlopidine.Approved
TiletamineTiletamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Vet Approved
TioconazoleThe serum concentration of Zolpidem can be increased when it is combined with Tioconazole.Approved
TipranavirThe metabolism of Zolpidem can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
TocilizumabThe serum concentration of Zolpidem can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Zolpidem can be decreased when combined with Tolbutamide.Approved
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Withdrawn
TolnaftateThe serum concentration of Zolpidem can be increased when it is combined with Tolnaftate.Approved, Vet Approved
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Experimental
TranylcypromineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
TrazodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Vet Approved
TrimethoprimThe metabolism of Zolpidem can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimetrexateThe serum concentration of Zolpidem can be increased when it is combined with Trimetrexate.Approved, Investigational
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
Uc1010Uc1010 may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Investigational
Valproic AcidValproic Acid may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
ValsartanThe metabolism of Zolpidem can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Zolpidem can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Zolpidem can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Zolpidem can be decreased when combined with Verapamil.Approved
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
VoriconazoleThe serum concentration of Zolpidem can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
XylazineXylazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Vet Approved
ZafirlukastThe metabolism of Zolpidem can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Illicit, Investigational
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZolazepamZolazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Vet Approved
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Should not be administered with or immediately after a meal.
References
Synthesis Reference

Markus Sauter, “Process for preparing zolpidem.” U.S. Patent US20020183522, issued December 05, 2002.

US20020183522
General References
  1. Lemmer B: The sleep-wake cycle and sleeping pills. Physiol Behav. 2007 Feb 28;90(2-3):285-93. Epub 2006 Oct 16. [PubMed:17049955 ]
  2. Depoortere H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Langer SZ, Bartholini G: Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther. 1986 May;237(2):649-58. [PubMed:2871178 ]
  3. Clauss RP, Guldenpfennig WM, Nel HW, Sathekge MM, Venkannagari RR: Extraordinary arousal from semi-comatose state on zolpidem. A case report. S Afr Med J. 2000 Jan;90(1):68-72. [PubMed:10721397 ]
  4. Schlich D, L'Heritier C, Coquelin JP, Attali P, Kryrein HJ: Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res. 1991 May-Jun;19(3):271-9. [PubMed:1670039 ]
  5. Maarek L, Cramer P, Attali P, Coquelin JP, Morselli PL: The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res. 1992 Apr;20(2):162-70. [PubMed:1521672 ]
External Links
ATC CodesN05CF02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (323 KB)
MSDSDownload (170 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9392
Caco-2 permeable+0.6638
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IINon-inhibitor0.7574
Renal organic cation transporterNon-inhibitor0.621
CYP450 2C9 substrateNon-substrate0.7412
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateInhibitor0.624
CYP450 2C9 inhibitorNon-inhibitor0.8331
CYP450 2D6 inhibitorNon-inhibitor0.8754
CYP450 2C19 inhibitorNon-inhibitor0.9119
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5265
Ames testNon AMES toxic0.5507
CarcinogenicityNon-carcinogens0.8352
BiodegradationNot ready biodegradable0.9928
Rat acute toxicity2.5614 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9831
hERG inhibition (predictor II)Non-inhibitor0.6928
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novadel pharma inc
  • Sanofi aventis us llc
  • Biovail laboratories international srl
  • Apotex inc
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Carlsbad technology inc
  • Dr reddys laboratories ltd
  • Genpharm inc
  • Hikma pharmaceuticals
  • Invagen pharmaceuticals inc
  • Lek pharmaceuticals dd
  • Mutual pharmacal co
  • Mylan pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
  • Synthon pharmaceuticals ltd
  • Teva pharmaceuticals usa inc
  • Torrent pharmaceuticals ltd
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • Wockhardt ltd
  • World gen llc
  • Meda pharmaceuticals
  • Pfizer inc
Packagers
Dosage forms
FormRouteStrength
TabletOral6.25 mg/1
Tablet, coatedOral12.5 mg/1
Tablet, coatedOral6.25 mg/1
Tablet, orally disintegratingSublingual10 mg
Tablet, orally disintegratingSublingual5 mg
TabletOral10 mg/1
TabletOral5 mg/1
Kit
TabletSublingual1.75 mg/1
TabletSublingual3.5 mg/1
TabletOral10 mg
TabletOral5 mg
KitOral
TabletSublingual10 mg/1
TabletSublingual5 mg/1
Tablet, coatedOral10 mg/1
Tablet, coatedOral5 mg/1
Tablet, extended releaseOral12.5 mg/1
Tablet, extended releaseOral6.25 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral5 mg/1
Tablet, film coated, extended releaseOral12.5 mg/1
Tablet, film coated, extended releaseOral6.25 mg/1
Spray, meteredOral5 mg/1
Prices
Unit descriptionCostUnit
Ambien cr 12.5 mg tablet6.19USD tablet
Ambien cr 6.25 mg tablet6.19USD tablet
Ambien 10 mg tablet6.11USD tablet
Ambien 5 mg tablet6.04USD tablet
Ambien CR 12.5 mg Controlled Release Tabs6.0USD tab
Ambien CR 6.25 mg Controlled Release Tabs6.0USD tab
Edluar 10 mg sl tablet5.0USD tablet
Edluar 5 mg sl tablet5.0USD tablet
Zolpidem tartrate 10 mg tablet2.73USD tablet
Zolpidem tartrate 5 mg tablet2.73USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6514531 Yes2000-06-012020-06-01Us
US6761910 No1999-09-242019-09-24Us
US7632517 No1997-10-012017-10-01Us
US7658945 No2007-04-152027-04-15Us
US7682628 No2005-02-162025-02-16Us
US8242131 No2009-08-202029-08-20Us
US8252809 No2005-02-162025-02-16Us
US8512747 No1999-09-242019-09-24Us
US9265720 No2010-05-132030-05-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point196 °CPhysProp
water solubility23 mg/mLNot Available
logP1.2Not Available
pKa6.2MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.0313 mg/mLALOGPS
logP3.15ALOGPS
logP3.02ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)5.65ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area37.61 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity93.58 m3·mol-1ChemAxon
Polarizability35.06 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-000i-1090000000-5429f5620534a2340098View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylimidazoles. These are polycyclic aromatic compounds containing a benzene ring linked to an imidazole ring through a CC or CN bond.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassImidazoles
Direct ParentPhenylimidazoles
Alternative Parents
Substituents
  • 4-phenylimidazole
  • 5-phenylimidazole
  • Imidazopyridine
  • Methylpyridine
  • Toluene
  • Benzenoid
  • Pyridine
  • N-substituted imidazole
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Vlainic J, Pericic D: Effects of acute and repeated zolpidem treatment on pentylenetetrazole-induced seizure threshold and on locomotor activity: comparison with diazepam. Neuropharmacology. 2009 Jun;56(8):1124-30. doi: 10.1016/j.neuropharm.2009.03.010. Epub 2009 Apr 1. [PubMed:19345234 ]
  4. Smith AJ, Alder L, Silk J, Adkins C, Fletcher AE, Scales T, Kerby J, Marshall G, Wafford KA, McKernan RM, Atack JR: Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol Pharmacol. 2001 May;59(5):1108-18. [PubMed:11306694 ]
  5. Pritchett DB, Seeburg PH: Gamma-aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem. 1990 May;54(5):1802-4. [PubMed:2157817 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Pritchett DB, Seeburg PH: Gamma-aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem. 1990 May;54(5):1802-4. [PubMed:2157817 ]
  2. Smith AJ, Alder L, Silk J, Adkins C, Fletcher AE, Scales T, Kerby J, Marshall G, Wafford KA, McKernan RM, Atack JR: Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol Pharmacol. 2001 May;59(5):1108-18. [PubMed:11306694 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Pritchett DB, Seeburg PH: Gamma-aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem. 1990 May;54(5):1802-4. [PubMed:2157817 ]
  2. Smith AJ, Alder L, Silk J, Adkins C, Fletcher AE, Scales T, Kerby J, Marshall G, Wafford KA, McKernan RM, Atack JR: Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol Pharmacol. 2001 May;59(5):1108-18. [PubMed:11306694 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 04, 2016 04:00